These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 21827390)

  • 1. Immunotherapy of kidney cancer.
    Grivas PD; Redman BG
    Curr Clin Pharmacol; 2011 Aug; 6(3):151-63. PubMed ID: 21827390
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recent developments in renal cell cancer immunotherapy.
    Wysocki PJ; Zolnierek J; Szczylik C; Mackiewicz A
    Expert Opin Biol Ther; 2007 May; 7(5):727-37. PubMed ID: 17477809
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The identification of renal cell carcinoma as a target for allogeneic based cancer immunotherapy.
    Childs RW; Igarashi T
    Exp Nephrol; 2002; 10(3):227-34. PubMed ID: 12053124
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Advances in immune-based therapies of renal cell carcinoma.
    Lam JS; Belldegrun AS; Figlin RA
    Expert Rev Anticancer Ther; 2004 Dec; 4(6):1081-96. PubMed ID: 15606335
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized phase II trial comparing two different sequence combinations of autologous vaccine and human recombinant interferon gamma and human recombinant interferon alpha2B therapy in patients with metastatic renal cell carcinoma: clinical outcome and analysis of immunological parameters.
    Schwaab T; Heaney JA; Schned AR; Harris RD; Cole BF; Noelle RJ; Phillips DM; Stempkowski L; Ernstoff MS
    J Urol; 2000 Apr; 163(4):1322-7. PubMed ID: 10737537
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [A malignus melanoma immunterápiájának lehetoségei].
    Ladányi A
    Magy Onkol; 2003; 47(1):113-7. PubMed ID: 12704464
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel immunotherapeutic strategies in development for renal cell carcinoma.
    Inman BA; Harrison MR; George DJ
    Eur Urol; 2013 May; 63(5):881-9. PubMed ID: 23084331
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cytokine-based immunotherapy for advanced kidney cancer: past results and future perspectives in the era of molecularly targeted agents.
    Porta C; Paglino C; Imarisio I; Bonomi L
    ScientificWorldJournal; 2007 Apr; 7():837-49. PubMed ID: 17619768
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PD-1 blockade therapy in renal cell carcinoma: current studies and future promises.
    Massari F; Santoni M; Ciccarese C; Santini D; Alfieri S; Martignoni G; Brunelli M; Piva F; Berardi R; Montironi R; Porta C; Cascinu S; Tortora G
    Cancer Treat Rev; 2015 Feb; 41(2):114-21. PubMed ID: 25586601
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunotherapy of metastatic renal cell cancer.
    Fishman M; Seigne J
    Cancer Control; 2002; 9(4):293-304. PubMed ID: 12228755
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Allogeneic stem cell transplantation as immunotherapy for renal cell carcinoma: from immune enhancement to immune replacement.
    Drachenberg D; Childs RW
    Urol Clin North Am; 2003 Aug; 30(3):611-22. PubMed ID: 12953759
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunotherapy for glioma: promises and challenges.
    Han SJ; Zygourakis C; Lim M; Parsa AT
    Neurosurg Clin N Am; 2012 Jul; 23(3):357-70. PubMed ID: 22748649
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adjuvant Therapy for High Risk Localized Kidney Cancer: Emerging Evidence and Future Clinical Trials.
    Lenis AT; Donin NM; Johnson DC; Faiena I; Salmasi A; Drakaki A; Belldegrun A; Pantuck A; Chamie K
    J Urol; 2018 Jan; 199(1):43-52. PubMed ID: 28479237
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Renal cell carcinoma: novel treatments for advanced disease.
    Huland E; Heinzer H
    Curr Opin Urol; 2003 Nov; 13(6):451-6. PubMed ID: 14560137
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adoptive immunotherapy with vaccine-primed lymph node cells secondarily activated with anti-CD3 and interleukin-2.
    Chang AE; Aruga A; Cameron MJ; Sondak VK; Normolle DP; Fox BA; Shu S
    J Clin Oncol; 1997 Feb; 15(2):796-807. PubMed ID: 9053507
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunotherapy and targeted therapy combinations in renal cancer.
    McDermott DF
    Curr Clin Pharmacol; 2011 Aug; 6(3):207-13. PubMed ID: 21827391
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Immunotherapy for advanced renal cell carcinoma].
    Aulitzky WE; Kaufmann M
    Urologe A; 2004 Jan; 43(1):85-92; quiz 93. PubMed ID: 15179984
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Donor lymphocyte infusion: the use of alloreactive and tumor-reactive lymphocytes for immunotherapy of malignant and nonmalignant diseases in conjunction with allogeneic stem cell transplantation.
    Slavin S; Morecki S; Weiss L; Or R
    J Hematother Stem Cell Res; 2002 Apr; 11(2):265-76. PubMed ID: 11983098
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of renal cell carcinoma: Current status and future directions.
    Barata PC; Rini BI
    CA Cancer J Clin; 2017 Nov; 67(6):507-524. PubMed ID: 28961310
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nonmyeloablative stem cell transplantation: reduced-intensity conditioning for cancer immunotherapy--from bench to patient bedside.
    Slavin S; Morecki S; Weiss L; Shapira MY; Resnick I; Or R
    Semin Oncol; 2004 Feb; 31(1):4-21. PubMed ID: 14970932
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.